复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

已收盘 12-15 16:08:35

61.100

-3.700

-5.71%

最高64.100	最低60.500	成交量56.91万
今开62.900	昨收64.800	日振幅5.56%
总市值332.08亿	流通市值99.85亿	总股本5.43亿
成交额3,511万	换手率0.35%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":61.1,"timestamp":1765786115007,"preClose":64.8,"halted":0,"volume":569100,"delay":0,"floatShares":163428541,"shares":543494853,"eps":1.6684540554522318,"marketStatus":"已收盘","change":-3.7,"latestTime":"12-15 16:08:35","open":62.9,"high":64.1,"low":60.5,"amount":35109657,"amplitude":0.055556,"askPrice":61.3,"askSize":200,"bidPrice":61.1,"bidSize":1300,"shortable":3,"etf":0,"ttmEps":1.6762347765024472,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":5,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":64.8,"openAndCloseTimeList":[[1765762200000,1765771200000],[1765774800000,1765785600000]],"volumeRatio":0.829609,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696/tweets","defaultTab":"tweets","newsList":[{"id":"2591649007","title":"医药日报：复宏汉霖新适应症获优先审评，君实生物双抗ADC出海获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649007","media":"药融链接","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591649007?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:06","pubTimestamp":1765789608,"startTime":"0","endTime":"0","summary":"君实生物双抗ADC获FDA临床试验批准，国际化研发取得新进展。02产品注册与审批复宏汉霖：其产品斯鲁利单抗注射液新增适应症的上市申请已获受理，并被纳入优先审评程序。04国际合作与出海君实生物：其针对EGFR/HER3的双特异性抗体偶联药物用于治疗晚期实体瘤的临床试验申请，已获得美国FDA批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215175631a44d99ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215175631a44d99ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","BK1574","BK1583","09939","01877","BK1515","02696","BK1161"],"gpt_icon":0},{"id":"2591691376","title":"恒生医疗保健指数跌幅扩大至2.75% 医药股普遍走低 科伦博泰生物(06990)跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591691376","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591691376?lang=zh_cn&edition=full","pubTime":"2025-12-15 11:11","pubTimestamp":1765768311,"startTime":"0","endTime":"0","summary":"金吾财讯 | 恒生医疗保健指数跌幅扩大至2.75%，医药股普遍走低，科伦博泰生物(06990)跌7.07%，百济神州(06160)跌5.35%，复宏汉霖(02696)跌5.32%，荣昌生物(09995)跌4.05%，康方生物(09926)跌3.61%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971535","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","LU1961090484.USD","LU2488822045.USD","BK1161","LU2778985437.USD","LU1303224171.USD","LU2476274308.USD","LU0588546209.SGD","LU2476274720.SGD","LU0417516571.SGD","LU2399975544.HKD","LU0348767384.USD","LU1794554557.SGD","06160","LU0561508036.HKD","159506","LU0417516738.SGD","LU0348825331.USD","BK1500","BK1583","LU0634319403.HKD","LU2328871848.SGD","IE00BPRC5H50.USD","LU0348735423.USD","LU1720050803.USD","LU1770034418.SGD","IE00B5MMRT66.SGD","09926","LU1251922891.USD","IE00B543WZ88.USD","159938","09939","BK1574","LU0307460666.USD","06990","02696","BK1515","LU0348783233.USD","LU1719994722.HKD","HK0000165453.HKD","09995","LU0348766576.USD","LU0417516902.SGD","BK1588","LU0540923850.HKD","LU0348784397.USD","LU1969619763.USD","LU0196878994.USD"],"gpt_icon":0},{"id":"2590571404","title":"复宏汉霖(02696)：汉斯状®联合化疗用于胃癌新辅助/辅助治疗的上市注册申请获国家药监局受理，并已纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2590571404","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590571404?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:48","pubTimestamp":1765529324,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，公司自主开发的汉斯状 (汉斯状)联合含铂化疗新辅助，在手术后辅助治疗，用于 PD-L1阳性的、可手术切除的胃癌患者的上市注册申请获国家药品监督管理局药品审评中心受理，并已纳入优先审评审批程序，将加速其上市审评进程。研究结果显示，汉斯状联合化疗对比安慰剂联合化疗可显著延长患者的无事件生存期，达到预设的优效性标准，并体现出较全程化疗更佳的安全性及耐受性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2590311980","title":"复宏汉霖(02696)：HLX22联合注射用HLX87分别用于BC一线治疗与BC neo的2/3期临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590311980","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590311980?lang=zh_cn&edition=full","pubTime":"2025-12-09 17:17","pubTimestamp":1765271869,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，HLX22联合注射用HLX87用于HER2阳性乳腺癌一线治疗，以及用于HER2阳性乳腺癌新辅助治疗的2/3期临床试验申请，分别获国家药品监督管理局批准。HLX22为本公司许可引进并后续自主研发的新型靶向HER2的单克隆抗体，潜在适应症包括胃癌和乳腺癌等实体瘤。目前，一项HLX87用于HER2阳性乳腺癌二线治疗的3期临床试验正于中国境内开展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BC","HK0000165453.HKD","BK4190","02696"],"gpt_icon":0},{"id":"2590344737","title":"每日卖空追踪 | 复宏汉霖 12月09日卖空量成交5100股，卖空比例为1.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590344737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590344737?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:30","pubTimestamp":1765269032,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间12月09日，跌0.23%，卖空量成交5100股，较上一交易日减少87.31%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163506a72cf2b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163506a72cf2b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"2590447323","title":"复宏汉霖12月09日主力净流出35.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2590447323","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590447323?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:15","pubTimestamp":1765268131,"startTime":"0","endTime":"0","summary":"12月09日, 复宏汉霖股价跌0.23%，报收65.30元，成交金额2789.4万元，换手率0.26%，振幅3.97%，量比0.59。复宏汉霖今日主力资金净流出35.3万元，上一交易日主力净流入20.1万元。该股近5个交易日下跌4.53%，主力资金累计净流出1561.2万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出3590.5万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120916180497981ca1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120916180497981ca1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"2589748738","title":"复宏汉霖(02696)：复妥宁®(枸橼酸伏维西利胶囊)获纳入国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589748738","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589748738?lang=zh_cn&edition=full","pubTime":"2025-12-07 18:39","pubTimestamp":1765103995,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，复妥宁获纳入《国家基本医疗保险、生育保险和工伤保险药品目录》乙类范围，获纳入的适应症为联合氟维司群用于既往接受内分泌治疗后出现疾病进展的激素受体阳性、人表皮生长因子受体2阴性的复发或转移性成年乳腺癌患者。新版国家医保药品目录将于2026年1月1日起正式实施。复妥宁系公司许可引进的创新型CDK4/6小分子抑制剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"2589834810","title":"122亿！国药控股大合作来了","url":"https://stock-news.laohu8.com/highlight/detail?id=2589834810","media":"赛柏蓝","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589834810?lang=zh_cn&edition=full","pubTime":"2025-12-04 18:33","pubTimestamp":1764844407,"startTime":"0","endTime":"0","summary":"01国药控股再次牵手复宏汉霖12月3日，复宏汉霖消息称，将重续与国药控股经销合作，合作期限为2026年1月1日至2028年12月31日。2023年-2025年9月，国药控股分别完成了19.17亿元、20.40亿元以及16.93亿元的销售额。在此背景下，国药控股与复宏汉霖再次达成合作，未来三年的产品销售总额上限高达122.24亿元。12月2日，国药控股官方微信消息称，近日与皮尔法伯制药进行了战略合作签约。在2025年上半年时，国药控股营收和归母净利润较同期分别下降2.95%和6.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204204517a723d0b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204204517a723d0b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01099","BK1500","BK1515","LU1115378108.SGD","LU0640798160.USD","HK0000165453.HKD","BK1197","02696","BK1161"],"gpt_icon":0},{"id":"2589834829","title":"每日卖空追踪 | 复宏汉霖 12月04日卖空量成交1900股，卖空比例为0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589834829","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589834829?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:30","pubTimestamp":1764837033,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间12月04日，涨0.75%，卖空量成交1900股，较上一交易日减少84.8%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163529952a7c40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163529952a7c40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"2588071073","title":"复宏汉霖落子乳腺癌赛道：与奥鸿药业签独家许可协议 伏维西利补全小分子管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2588071073","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588071073?lang=zh_cn&edition=full","pubTime":"2025-12-04 10:32","pubTimestamp":1764815532,"startTime":"0","endTime":"0","summary":"12月3日，复宏汉霖（02696）发布公告，公司与奥鸿药业订立合作协议，奥鸿药业同意授予公司于区域内及领域内商业化运营许可产品的独家许可权。该合作协议是在双方于2025年8月7日签署的合作备忘录基础上达成的，合作备忘录已于签署合作协议时自动终止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512043582466296.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"2588207135","title":"复宏汉霖重续与国药控股经销协议 年度上限逐年递增","url":"https://stock-news.laohu8.com/highlight/detail?id=2588207135","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588207135?lang=zh_cn&edition=full","pubTime":"2025-12-04 09:59","pubTimestamp":1764813590,"startTime":"0","endTime":"0","summary":"12月3日，复宏汉霖（02696）发布公告，宣布与国药控股的经销框架协议（2025重续）已达成，该协议的初始期限自2023年1月1日起至2025年12月31日止，现已自动续期三年，新的协议有效期自2026年1月1日至2028年12月31日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512043582422282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1115378108.SGD","BK1161","LU0640798160.USD","BK1515","BK1197","01099","BK1500","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"1168680147","title":"上海复宏汉霖(2696)将于12月31日召开临时股东大会 审议续签经销框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1168680147","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168680147?lang=zh_cn&edition=full","pubTime":"2025-12-03 22:06","pubTimestamp":1764770765,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司(2696)将于2025年12月31日(星期三)上午九时，在中国上海市徐汇区宜州路188号B8幢10楼会议室举行临时股东大会。主要议案包括审议并酌情批准与国药控股股份有限公司签订的“国控经销框架协议(2025重续)”及相关年度上限。\n根据公告，自2025年12月24日至12月31日(包括首尾两日)暂停办理股份过户登记。股东如需委派代表参加，应在12月30日上午九时前完成委托手续。于当日名列公司股东名册的股东将有权出席并投票。会议将以投票方式表决，结果将在香港交易及结算所有限公司及公司网站刊发。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"2588904122","title":"复宏汉霖(02696)就枸橼酸伏维西利胶囊与奥鸿药业订立合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2588904122","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588904122?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:52","pubTimestamp":1764769923,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 公布，于2025年12月3日，公司与奥鸿药业订立合作协议，据此，奥鸿药业同意授予集团于区域内及领域内商业化运营许可产品的独家许可权。许可产品作为CDK4/6抑制剂，已获批用于HR+、 HER2–的乳腺癌治疗。许可产品契合公司在乳腺癌领域的商业化布局，与公司现有的其他乳腺癌管线产品具有商业协同性。引进许可产品有助于丰富公司管线，以及有助于借助集团现有的乳腺癌商业化团队和资源提升集团未来收入规模。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)就枸橼酸伏维西利胶囊与奥鸿药业订立合作协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK1161","02696"],"gpt_icon":0},{"id":"1148190059","title":"复宏汉霖 - 锦州安万科药业将授予独家许可以商业化复凡西尼胶囊","url":"https://stock-news.laohu8.com/highlight/detail?id=1148190059","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148190059?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:49","pubTimestamp":1764769749,"startTime":"0","endTime":"0","summary":"复宏汉霖 - 锦州安万科药业将授予独家许可以商业化复凡西尼胶囊","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2588034171","title":"复宏汉霖(02696)：地舒单抗生物类似药HLX14的上市注册申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588034171","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588034171?lang=zh_cn&edition=full","pubTime":"2025-12-02 18:39","pubTimestamp":1764671983,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本集团自主研发的地舒单抗生物类似药HLX14的上市注册申请获国家药品监督管理局药品审评中心受理。本次HLX14的上市注册申请主要基于HLX14对比其参照药产生的数据，包括分析相似性研究、非临床和临床比对研究。HLX14是本集团自主研发的地舒单抗生物类似药，2025年下半年，HLX14两个产品分别于美国、欧盟及英国批准上市，获批适应症覆盖其原研产品于当地已获批的所有适应症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：地舒单抗生物类似药HLX14的上市注册申请获国家药品监督管理局受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2588709367","title":"复宏汉霖PD-L1 ADC II期结果读出；*ST苏吴进入退市整理期｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2588709367","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588709367?lang=zh_cn&edition=full","pubTime":"2025-12-02 07:01","pubTimestamp":1764630081,"startTime":"0","endTime":"0","summary":"丨2025年12月2日星期二丨NO.1复宏汉霖PD-L1ADCII期结果读出11月26日，复宏汉霖发布公告表示将在ESMOAsia2025大会上公布多项药物的临床数据。亮点之一在于核心资产PD-L1ADC药物HLX43在宫颈癌领域的II期研究结果。点评：针对PD-L1ADC开发在研管线并不多，目前进度最快的是辉瑞的PF-08046054，已至临床III期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512023579600777.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023579600777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","600200","PD","BK4080","BK0012","BK0239","BK0188","BK4231","159938","BK0028","BK1515","BK1574","09939","BK1161","LU1169590202.USD","02696","LU1169589451.USD","BK4023","HK0000165453.HKD","ADC"],"gpt_icon":0},{"id":"2588538083","title":"复星医药1类新药获批临床，太龙药业控制权生变，ST中珠子公司合同纠纷案获重审，福安药业头孢托仑匹酯颗粒过评","url":"https://stock-news.laohu8.com/highlight/detail?id=2588538083","media":"谈医说药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588538083?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:46","pubTimestamp":1764600404,"startTime":"0","endTime":"0","summary":"头孢托仑匹酯颗粒适用于敏感菌引起的浅表性皮肤感染、深部皮肤感染等疾病。复星医药：公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司收到国家药品监督管理局关于同意HLX37注射液开展临床试验的批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201233339a4c619a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201233339a4c619a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02696","BK1515","BK1593","02196","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"2588728216","title":"复宏汉霖(02696)自主研发的HLX37在晚期/转移性实体瘤患者中的1期临床试验申请获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588728216","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588728216?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:12","pubTimestamp":1764580363,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)公布，近日，公司自主研发的HLX37(重组人源化抗PD-L1与抗VEGF双特异性抗体注射液)(HLX37)在晚期/转移性实体瘤患者中的1期临床试验申请(IND)获国家药品监督管理局(NMPA)批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)自主研发的HLX37在晚期/转移性实体瘤患者中的1期临床试验申请获NMPA批准","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"2588083577","title":"每日卖空追踪 | 复宏汉霖 12月01日卖空量成交6900股，卖空比例为2.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588083577","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588083577?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:30","pubTimestamp":1764577832,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间12月01日，涨0.65%，卖空量成交6900股，较上一交易日减少21.59%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201163446a4c551aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201163446a4c551aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2588835920","title":"复宏汉霖12月01日主力净流入111.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2588835920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588835920?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:15","pubTimestamp":1764576912,"startTime":"0","endTime":"0","summary":"12月01日, 复宏汉霖股价涨0.65%，报收69.50元，成交金额2244.7万元，换手率0.20%，振幅3.62%，量比0.45。复宏汉霖今日主力资金净流入111.3万元，上一交易日主力净流出118.2万元。该股近5个交易日上涨4.33%，主力资金累计净流入302.5万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出1692.3万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120116154097894a43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120116154097894a43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0407},{"period":"1month","weight":0.0485},{"period":"3month","weight":-0.1849},{"period":"6month","weight":0.3556},{"period":"1year","weight":1.9058},{"period":"ytd","weight":1.7342}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.052523},{"month":2,"riseRate":0.666667,"avgChangeRate":0.108951},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016995},{"month":4,"riseRate":0.833333,"avgChangeRate":0.128587},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.007782}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}